First, a few words about the Rules of our Message Board:
1) Medizone-related posts ONLY. NO other stocks may be mentioned.
3) Limit alerts to what's currently occurring, or potential action.
4) There will be NO attacking a board member for their trading styles regardless of your personal feelings. NO EXCEPTIONS. We are all here to make $$.
6) All IBOX requests/suggestions must be done by PM to a MOD
7) If you have relevant infomation, PLEASE back up with a link if available.
8) HAVE FUN AND LET'S MAKE SOME $$$$!
The Medizone Story
Medizone International (OTC: MZEI) is a research and development company engaged in developing its AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. We have received several US patents for our AsepticSure System, plus patents that cover most other parts of the developed world.
Most recently, we were awarded the European Union's CE Mark, which removes any regulatory barriers for marketing in the European Union.
We are currently pursuing final regulatory approval for marketing in the US. At the same time, we are actively discussing marketing options in other regions where we have the necessary approvals, while also exploring various applications of AsepticSure's exceptional disinfectant power in non health-related fields.
Current Methods of Sterilization Have Failed
At first glance, the solution to hospital infections would seem to be quite straightforward: intense preventative measures, involving the thorough cleaning of any infected area. Indeed, every health-care facility invests tremendous effort to ensure that any possible source of potential re-infection of a patient or worker is destroyed.
The problem is that present methods of cleaning, disinfection and sterilization are simply not working. Current cleaning protocols for the sanitization of hospitals have become increasingly ineffective, resulting in an accumulation of deadly bacteria throughout facilities.
Even innovative technologies such as UV light "robots" yield the same limited results.
Recent research conducted by Microsearch Laboratories demonstrated that a cleaning mop collected from a New York hospital, cleaned in the standard manner and then tested, was found to have in excess of 150,000 colonies of C. difficile. Results like this raise concerns about the efficacy of current cleaning and disinfecting procedures.
To make matters even worse, non-medical surfaces - e.g. carpets, bedding, curtains, and porous materials in ceilings - that have been impregnated with highly resistant nosocomial pathogens (in particular, spore formers such as C. difficile), cannot be disinfected with currently available agents and processes. Over time, these pathogens may accumulate in dangerously high concentrations.
Furthermore, research in our own laboratory in Kingston, Ontario, has identified another major factor in the failure of current methods. Although the protocols in use do eradicate a percentage of the existing pathogens, they leave behind a still-significant number (3-log). We have demonstrated repeatedly that the "survivors" of standard cleaning methods rapidly regenerate, and within several days, the original level of pathogens is restored to the treated area.
The inevitable result is a constant cycle of infection.
Government, on both the state and federal levels, is becoming more aware of the dimensions of the problem, but has not yet found an appropriate formula to address it. The tables below tell the story:
AsepticSure Breaks the Deadly Infection Cycle
The AsepticSure treatment uses a mixture of ozone and a specific level of hydrogen peroxide, forming a new compound called trioxidane. In peer-reviewed testing, as reported in The American Journal of Infection Control (May, 2011), AS consistently produced a reduction of at least 6-log (sterilization level) against all pathogens, rendering the affected area completely free of any infectious agents. This is how the cycle of infection is broken!
There has been remarkable confirmation of AsepticSure's tranformative potency in a real-life situation.
In June of 2013, Quinte Health Care’s Belleville General Hospital in Ontario, Canada, was confronted with recurring outbreaks of MRSA (Methicilllin-Resistant Staphylococcus Aureus). The staff turned to Medizone to employ AsepticSure to counter this issue.
Here is how the situation was described by the Chief of Staff of Belleville General, Dr. Dick Zoutman:
"Dr. Michael Shannon and other team members have been performing AsepticSure disinfection treatments at our hospital. These efforts have proven so successful that we have now fully implemented the AsepticSure protocols into the management of this most recent MRSA outbreak.
" On average we have had one or two new MRSA cases per month on the ward. This is in keeping with averages being reported within the health care system nationally. In June we noted a rapidly spreading MRSA problem on the ward that reached seven rooms over a short period of time. That is when we began using Medizone International’s AsepticSure® room disinfection system. It is the only system we know of that can actually eliminate 100% of infective pathogens with a single room treatment.
“The results were immediate. The MRSA was immediately and entirely eliminated from the ward. The AsepticSure system was straightforward to use and quick, with complete room disinfection occurring in an hour. To prove to ourselves that the AsepticSure system was working, we performed cultures of 120 surfaces of the treated rooms before and after the AsepticSure system was used. The results were amazing. Virtual complete elimination of all bacteria on the room surfaces after AsepticSure was used in the rooms.”
But the story doesn't end there!
Here's what Dr. Zoutman reported six months after the initial treatment of the ward:
"...the longer-term effects were not fully appreciated until after a six-month follow-up had been completed. Only then was it realized that not only had the rooms remained free of MRSA, no further cases of MRSA were noted on the ward during this period.”
“It is noteworthy in this regard,” stated Dr. Michael E. Shannon, President of Medizone International and a former Director General of the Laboratory Centre for Disease Control, Health Canada, “that in addition to full room disinfection, all support equipment associated with each contaminated room were also disinfected using AsepticSure – and this may have played an important role as well in virtually eliminating MRSA from the ward. These mobile pieces of patient care equipment are notoriously hard to clean by hand. AsepticSure made disinfecting them very easy.
“Given that hospital acquired infections are now considered to be the fourth leading cause of death in both the United States and Canada, this could be a game changer.
“Not only has this result at Quinte Health Care Belleville General Hospital demonstrated a new standard for what a clean hospital could be,” stated Dr. Shannon, “but thousands of lives might be saved with the wide adoption of AsepticSure, while actually reducing the overall cost of hospital care by avoiding the expense of treating these largely preventable infections. The United States Center for Disease Control places the cost per each new infection at $25,000.”
- Medizone has a 23-year history in the field of medical therapeutics with ozone.
Medizone has initiated a joint program with Cogmedix, of Worcester, Mass., to develop the state-of-the-art AsepticSure™ system.
This technology will feature a new "Ozone Destruct" scrubbing system intended to rapidly detoxify hospital working spaces following exposure to ozone.
The AsepticSure technology will have an ozone producing capacity 4 times greater than what is necessary under normal hospital circumstances, guaranteeing total disinfection in all conditions.
The AsepticSure™ system will also include a gas vaporization component, and a stand-alone ozone scrubbing system, adaptable to all hospital environments and space requirements.
Medizone International's Corporate Strategy
Our focus has been primarily, though not exclusively, in the field of hospital sterilization. This development pathway is based in part on a review of published data on hospital-derived infections. This is an area of rapidly growing concern in the medical community, which is also subject to increasing governmental scrutiny and regulation on both a state and federal level both in the United States and in Canada, the UK and Europe.
Medizone's extensive experience with ozone and its bio-oxidative qualities has contributed greatly in pursuing this initiative. Near-term efforts have been directed toward one of the Company's founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing virtually all biological fluids, which includes blood, serum, and plasma and its fractionates, as well as all biologically contaminated equipment and spaces.
Medizone is discovering that its unique ozone generating technologies when combined with other new emerging technologies will play a vital role in addressing what public health officials and surgeons world-wide are beginning to recognize as "The Silent Epidemic": CA-MRSA and HA-MRSA (Richard P. Evans, MD, American Academy of Orthopedic Surgeons, May 2008, "AAOS Study").
Partnership with a Multinational Corporation
Following proof of reliability of the first commercially delivered units, Medizone will have optimized its strengths as a research and development company. It then expects to partner with a large corporation embedded in the hospital sector for increased manufacturing capacity, sales, and service.
Who are the People Behind Medizone?
David A. Dodd, CEO
Mr. Dodd became the CEO of Medizone Int. in September, 2017. His appointment marks a significant enhancement of our leadership team, and comes at a critical time for Medizone, as we transition into the commercialization of the AsepticSure system.
Mr. Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. From April 2013 until August 2017, Mr. Dodd served as President, CEO of Aeterna Zentaris Inc. (NASDAQ: “AEZS”; www.aezsinc.com); he also served as Chairman of the Board from May 2014 until May 2016. From December 2007 to June 2009, Mr. Dodd was President, CEO and Chairman of BioReliance Corporation, a leading provider of biological safety and related testing services. From October 2006 to April 2009, he served as non-executive Chairman of Stem Cell Sciences Plc., where he oversaw the development and implementation of a strategic growth plan, implementation of an experienced executive team, and the sale of the Company to Stem Cells, Inc., in April 2009.
During Mr. Dodd's six-year tenure as President, CEO and Director of Serologicals Corporation, the market value of that company increased from $85 million in June 2000 to an all-cash sale to Millipore Corporation in July 2006 for $1.5 billion. That successful transformation followed his five-year term as President and CEO of Solvay Pharmaceuticals, Inc. and as Chairman of its subsidiary Unimed Pharmaceuticals, Inc. Prior to that, Mr. Dodd held various senior management positions at Wyeth-Ayerst Laboratories, the Mead Johnson Laboratories Division at Bristol-Myers Squibb, and Abbott Laboratories.
Currently, he serves as Chair, Board of Directors, of GeoVax, Inc., a biotechnology company developing innovative, patented HIV/AIDS vaccines; as a Director on the Board of Aruna Biomedical, a privately-held life science development company focused on the development and commercialization of stem cell research products and services; and, as a Director on the Board of PNP Therapeutics, a clinical stage company, developing a novel nucleoside-booster treatment for solid tumor mass cancers.
He also serves as CEO of RiversEdge BioVentures LLC ("RiversEdge"), which he founded in 2009. RiversEdge is an investment and advisory firm focused on the life sciences and pharmaceutical industry.
He is a frequently invited speaker and panelist at business and economic development conferences, as well as various conferences focused on the life sciences and pharmaceutical industry. He is a recipient of the Oglethorpe Award for UK-US Business Relationships, the Georgia BIO Industry Growth Award, and the FastTech 50 Growth Company Award (2000-2006) while leading Serologicals Corporation.
Mr. Dodd holds Bachelor of Science and Master of Science degrees from Georgia State University, and completed the Harvard Business School of Advanced Management Program. His numerous public service activities include the American Foundation for Suicide Prevention, and the Board of Directors of the Institute of Bioengineering and Bioscience at Georgia Institute of Technology.
Dr. Michael E. Shannon
President & Director of Medical Affairs
Dr. Shannon received his medical degree from Queen's University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years.
He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments, he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.
In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General's office to conduct a cost-benefit analysis of all government sponsored pharmacare programs, and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004.
Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (equivalent to the US Center for Disease Control) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, which included the overnight construction of a mobile hospital and involved hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.
Dr. Shannon has been actively engaged in medical bio-oxidative (O3-based) research since 1987, and was directly responsible for the first ever human clinical trial in North America, which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.
Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed the position of Director of Medical Affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health. Subsequently, he was also named President of Medizone Int.
David A. Esposito
Chairman, Board of Directors
Mr. Esposito became a member of Medizone's BOD several years ago, and also served as Interim CEO from March, 2017, until September of the same year. When David Dodd assumed the role of permanent CEO, Mr. Esposito became the Chairman of the BOD.
He presently serves as the President and CEO of Armune Bioscience. Mr. Esposito has extensive experience in sales, marketing, and commercial strategy over many years. He was President of Phadia US Inc. (allergy and autoimmune diagnostics), and played a pivotal role in the sale of the business to Thermo Fisher Scientific for $3.5B USD in 2011. David began his career with Merck & Co. Inc., as a sales representative and subsequently served in various senior management positions. He led commercial strategy for the US Division and played a key role in Merck’s efforts to develop a New Commercial Model in the pharmaceutical industry.
David is a combat veteran. He led an infantry platoon with the 101st Airborne Division through several combat operations and was recognized with a Bronze Star for combat action in Iraq in 1991. David has a B.S. from the United States Military Academy at West Point and a MBA from Syracuse University.
Medizone's Consulting Team
Dr. Dick Eric Zoutman
Professor and Chair,
Divisions of Medical Microbiology and of Infectious Diseases, Queen's University
Medical Director of Infection Prevention and Control Services,
University Hospitals, Kingston, Ontario
Dr. Dick Zoutman has been practicing medicine for over 20 years and specializes in Internal Medicine, Infectious Diseases and Medical Microbiology at Queen's University at Kingston. A primary focus of his investigative work has been understanding the prevention and control of healthcare-associated infections and related medical errors. Using a systems analysis approach to examine healthcare operations, Dr. Zoutman has evaluated antibiotic prescribing and utilization in the community, acute care and long term care sectors. He has shed light on the factors that lead to the over-prescribing of antibiotics in family practice, as well as the failure of hospitals to successfully prevent surgical wound infections by properly prescribing antibiotics to patients undergoing major surgery. Dr. Zoutman continues to examine the impact of hospital resource allocation and adverse infectious events, as well as the use of information systems to improve the quality of patient care and to reduce hospital acquired infections. Dr. Zoutman's work and collaborations have spanned the globe from North America, South America, the Balkans, the Middle East and Africa.
He is Physician-Director of the Board of the Community and Hospital Infection Control Association of Canada. During the 2003 outbreak of SARS in Toronto, Dr. Zoutman chaired the Ontario SARS Scientific Advisory Committee responsible for advising the Ontario government on outbreak management strategies.
Dr. Zoutman is Chair of the National Bioterrorism Contingency Task Force for Hospitals, and a member of the Infection Control Guidelines Steering Committee and the Canadian Nosocomial Infection Surveillance Program. Dr. Zoutman is also Chief of the Department of Medical Microbiology and Medical Director of Infection Prevention and Control at the South Eastern Ontario Health Sciences Center in Kingston. Dr. Zoutman is professor of Pathology & Molecular Medicine, of Community Health and Epidemiology, and of Medicine in the Faculty of Health Sciences at Queen's University.
Dr. Ronald K. St. John
As a board-certified physician in preventive medicine, with post-graduate training in internal medicine, infectious diseases, and public health, Dr. St. John has 35 years of experience in the management of medical science for public health programs, legislation, and policy development. During his career, he has developed and managed large and small scale infectious disease control programs in domestic and international environments. Shortly before the 9/11 attacks in the US, he was appointed as a Director-General in the Canadian Department of Health with responsibility for developing Canada's first Centre for Emergency Preparedness and Response for crises and disasters affecting the health of the public. He retired from this position in February 2007.
Dr. St. John began his public health career as a commissioned officer in the US Public Health Service, assigned to the US Centers for Disease Control and Prevention. Through his work in domestic and international organizations, he acquired an extensive understanding of US Public Health Service institutions, the US and Canadian governments both on a national and a state/provincial level, the World Health Organization, the Pan American Health Organization (The WHO's Regional Office for the Americas), and both domestic and international non-governmental and development organizations.
During his tenure with the Canadian Department of Health and subsequently the Public Health Agency of Canada, he rebuilt the Canadian Quarantine Service, co-founded the Global Public Health Intelligence Network (GPHIN - a 24/7 global electronic monitoring system of all infectious disease outbreaks worldwide), modernized the Canadian National Emergency Stockpile System (a national network of strategically placed depots containing emergency medical supplies worth over $300 M) and established the first federal focus for medical counter-terrorism.
Dr. St. John graduated from three distinguished Ivy League Universities (BA from Yale University, MD degree from Columbia University and Masters in Public Health from Harvard University).
Canada NOW Magazine Publishes AsepticSure Story
As of May 13, 2016, the registrant had 369,934,068 shares of common stock issued and outstanding.
Profile Facts and Share Structure:
|Float ||Not Available |
|Exchange ||OTCBB |
|Reporting Status ||Fully Reporting |
|Shares Authorized || |
395m / 50m preferred
Shares Issued / Diluted
|352m (est) |
|Years in Business || |
Canadian Foundation for Global Health The Canadian Foundation for Global Health (CFGH), an affiliate of Medizone International, was founded under Canadian Federal Law as a not-for-profit Canadian Corporation headquartered in Ottawa, Ontario, Canada.
Michael E. Shannon, M.A.,M.Sc.,MD serves as the President of the Canadian Foundation for Global Health. Dr. Shannon is also the President and Director of Medical Affairs of Medizone International, and a member of Medizone's Board of Directors.
The Foundation has attracted a broad spectrum of the most highly qualified scientists, infectious disease specialists and other medical professionals from diverse fields of interest to serve on its Board of Directors, Science Advisory Board and as Principal Investigators.
Medizone's Board of Directors have adopted a business philosophy of "creating a corporate paradigm in which the corporation's profit follows its social contribution". The establishment of this foundation fits into that paradigm in a few ways: first, by being positioned to attract the highest caliber professionals to our research projects.
But in addition, it is envisioned that as Medizone's products and treatments become ready for market, the Foundation may play a vital role as a distribution source for developing countries by providing price reductions, depending on the country's needs and the availability of international assistance. We intend to make efforts through both the for-profit and the non-profit sectors to make affordable medical solutions as widely available as possible for the people of the planet.
While the Foundation's current focus remains on the development of the Medizone AsepticSure™ hospital sterilization initiative, we envision that in the future the Foundation may become involved in other projects that may or may not be related to the work of Medizone.